Agentix's Losses Widen Amid Soaring R&D, Cash Dwindles to $4,412

TL;DR

**AGTX is burning cash faster than it can find it, making it a high-risk bet with a 'going concern' warning that screams insolvency.**

AI Summary

Agentix Corp. (AGTX) reported a net loss of $185,824 for the three months ended June 30, 2025, an increase from the $150,717 net loss in the same period of 2024, representing a 23.3% deterioration. Total operating expenses rose significantly by 32.4% to $200,342 in Q2 2025 from $151,305 in Q2 2024, driven primarily by a 79.8% increase in research and development costs to $100,000. The company's cash position remains precarious, with only $4,412 in cash as of June 30, 2025, down from $4,477 on March 31, 2025. Current liabilities totaled $3,276,178, including $2,148,663 in accounts payable to related parties and a $343,000 note payable to a related party, indicating a heavy reliance on related-party financing. The accumulated deficit expanded to $6,707,352, and the company explicitly stated substantial doubt about its ability to continue as a going concern due to insufficient cash and negative operating cash flows of $118,371 for the quarter. Despite a foreign exchange gain of $15,140, interest expense more than doubled to $21,226.

Why It Matters

Agentix's deepening losses and critically low cash balance of $4,412 raise significant red flags for investors, signaling severe liquidity issues and an unsustainable operational model. The substantial reliance on related-party financing, with $2,148,663 in related-party payables, suggests limited access to external capital and potential governance concerns. For employees and customers, the 'going concern' warning indicates high job insecurity and potential disruption to any ongoing clinical research. In the competitive biotechnology landscape, AGTX's inability to secure adequate funding for its metabolic disease therapies puts it at a severe disadvantage, making it highly unlikely to bring any product to market without a major capital infusion.

Risk Assessment

Risk Level: high — The company explicitly states 'substantial doubt about the Company's ability to continue as a going concern' due to an accumulated deficit of $6,707,352, a net loss of $185,824, negative cash flows from operating activities of $118,371, and a critically low cash balance of $4,412 as of June 30, 2025. This severe financial distress, coupled with a heavy reliance on related-party debt, indicates an extremely high risk of business failure.

Analyst Insight

Investors should avoid Agentix Corp. (AGTX) given the explicit 'going concern' warning, critically low cash balance of $4,412, and increasing losses. The company's financial state suggests a high probability of further dilution or bankruptcy, making it an unsuitable investment for all but the most speculative, risk-tolerant traders.

Financial Highlights

total Assets

$4,412

total Debt

$3,276,178

net Income

-$185,824

eps

$ (0.00)

cash Position

$4,412

Key Numbers

• $185,824 — Net Loss (for the three months ended June 30, 2025, increased from $150,717 in Q2 2024)
• $4,412 — Cash on Hand (as of June 30, 2025, down from $4,477 on March 31, 2025)
• $200,342 — Total Operating Expenses (for the three months ended June 30, 2025, up from $151,305 in Q2 2024)
• $100,000 — Research and Development Expenses (for the three months ended June 30, 2025, up from $55,501 in Q2 2024)
• $6,707,352 — Accumulated Deficit (as of June 30, 2025, indicating significant historical losses)
• $3,276,178 — Total Current Liabilities (as of June 30, 2025, exceeding total assets of $4,412)
• $2,148,663 — Accounts Payable - Related Parties (as of June 30, 2025, a significant portion of current liabilities)
• $343,000 — Note Payable - Related Party (as of June 30, 2025, increased from $243,000 on March 31, 2025)
• $118,371 — Net Cash Used in Operating Activities (for the three months ended June 30, 2025)
• 40,066,951 — Common Shares Outstanding (as of June 30, 2025 and March 31, 2025)

Key Players & Entities

• Agentix Corp. (company) — registrant
• SEC (regulator) — Securities and Exchange Commission
• FairWind Energy, Inc. (company) — former name of Agentix Corp.
• GSL Healthcare, Inc. (company) — wholly owned subsidiary of Agentix Corp.
• AB Merger LLC (company) — wholly owned subsidiary of Agentix Corp.
• Agentix Australia Pty Ltd (company) — wholly owned subsidiary of Agentix Corp.
• Applied Biopharma (company) — wholly owned subsidiary of Agentix Corp.

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: The company has stated substantial doubt about its ability to continue as a going concern due to insufficient cash and negative operating cash flows. As of June 30, 2025, cash on hand was only $4,412, while current liabilities were $3,276,178. The accumulated deficit has reached $6,707,352.
• Heavy Reliance on Related-Party Financing [high — financial]: A significant portion of current liabilities is owed to related parties, totaling $2,148,663 in accounts payable and $343,000 in notes payable as of June 30, 2025. This concentration of debt with related entities poses a risk if these parties are unable or unwilling to continue providing financial support.
• Increasing Operating Expenses [medium — operational]: Total operating expenses increased by 32.4% to $200,342 in Q2 2025 from $151,305 in Q2 2024. This surge was primarily driven by a 79.8% increase in research and development costs, which rose to $100,000 from $55,501 year-over-year.
• Deteriorating Net Loss [medium — financial]: The net loss for the three months ended June 30, 2025, was $185,824, a 23.3% increase from the $150,717 net loss reported in the same period of 2024. This widening loss exacerbates the company's financial strain.
• Rising Interest Expenses [low — financial]: Interest expense more than doubled to $21,226 in Q2 2025 from $7,635 in Q2 2024. This increase, despite a foreign exchange gain, adds to the company's overall cost of capital and reduces profitability.

Industry Context

Agentix Corp. operates in a sector likely characterized by high research and development investment and significant regulatory oversight. The competitive landscape often involves established players and nimble startups vying for market share and funding. Industry trends may include rapid technological advancements, evolving consumer demands, and increasing pressure for sustainable and ethical practices.

Regulatory Implications

As a publicly traded entity, Agentix Corp. is subject to SEC regulations and reporting requirements. The company's going concern disclosure and significant related-party transactions could attract scrutiny from regulators and auditors, potentially leading to increased compliance burdens or investigations.

What Investors Should Do

1. Monitor related-party transactions closely: Assess the terms and sustainability of financing from related parties, as this is a critical source of funds and a potential risk if withdrawn.
2. Evaluate R&D spending effectiveness: Understand the strategic rationale and potential return on the significant increase in R&D expenses ($100,000 in Q2 2025) to determine if it justifies the increased operational costs.
3. Assess cash burn rate and runway: With only $4,412 in cash and negative operating cash flow, investors should scrutinize the company's ability to secure additional funding to sustain operations beyond the immediate term.
4. Consider the going concern warning: Recognize the high probability of financial distress and potential for liquidation or significant dilution if new capital is not raised or operations do not improve drastically.

Key Dates

• 2025-06-30: End of Second Quarter 2025 — Reported a net loss of $185,824 and a severely diminished cash position of $4,412, highlighting significant going concern issues.
• 2025-03-31: End of First Quarter 2025 — Cash position was $4,477, and the note payable to a related party was $243,000, indicating a slight decrease in cash and an increase in related-party debt in the subsequent quarter.
• 2024-06-30: End of Second Quarter 2024 — Reported a net loss of $150,717 and total operating expenses of $151,305, providing a baseline for comparison of the significant deterioration in Q2 2025.

Glossary

Accumulated deficit

The cumulative net losses of a company since its inception, minus any cumulative net profits. It represents a deficit in retained earnings. (Indicates the company has incurred more losses than profits over its history, reaching $6,707,352 as of June 30, 2025.)

Going concern

A business's ability to continue operating for the foreseeable future without the threat of liquidation. Auditors assess this based on financial health and operational viability. (The company explicitly states substantial doubt about its ability to continue as a going concern, a critical warning for investors.)

Related parties

Entities or individuals that have the ability to control or significantly influence the financial or operating decisions of another entity. Transactions between related parties require disclosure. (Agentix Corp. heavily relies on financing from related parties, with significant accounts payable and notes payable to them, totaling over $2.49 million.)

Operating Expenses

Costs incurred by a company in its normal business operations, excluding costs of goods sold and interest/taxes. Includes R&D, G&A, and professional fees. (Total operating expenses increased significantly by 32.4% in Q2 2025, driven by R&D, impacting the company's net loss.)

Foreign exchange gain

Profits realized from the fluctuation of currency exchange rates when a company holds assets or liabilities denominated in a foreign currency. (While the company reported a $15,140 foreign exchange gain in Q2 2025, it was insufficient to offset the overall increase in net loss and interest expenses.)

Year-Over-Year Comparison

Compared to the prior year's second quarter, Agentix Corp. has experienced a significant financial downturn. Total operating expenses have surged by 32.4% to $200,342, primarily due to a 79.8% increase in R&D costs. This has led to a 23.3% wider net loss of $185,824. The company's cash position has remained critically low, while current liabilities, particularly those owed to related parties, have increased, exacerbating financial fragility.

Key Financial Figures

• $0.001 — were 40,066,951 shares of common stock, $0.001 par value per share, outstanding. AGEN

Filing Documents

• agtx_10q.htm (10-Q) — 353KB
• agtx_ex311.htm (EX-31.1) — 14KB
• agtx_ex312.htm (EX-31.2) — 14KB
• agtx_ex321.htm (EX-32.1) — 4KB
• 0001477932-25-006197.txt ( ) — 1641KB
• agtx-20250630.xsd (EX-101.SCH) — 16KB
• agtx-20250630_lab.xml (EX-101.LAB) — 113KB
• agtx-20250630_cal.xml (EX-101.CAL) — 24KB
• agtx-20250630_pre.xml (EX-101.PRE) — 86KB
• agtx-20250630_def.xml (EX-101.DEF) — 32KB
• agtx_10q_htm.xml (XML) — 127KB

Financial Information

Part I. Financial Information Item 1.

Financial Statements

Financial Statements F-1 Consolidated Balance Sheets at June 30, 2025 (Unaudited) and March 31, 2025 (Audited). F-1 Unaudited Consolidated Statements of Operations for the three months ended June 30, 2025 and 2024. F-2 Unaudited Consolidated Statements of Changes in Stockholders' Deficit for the three months ended June 30, 2025 and 2024. F-3 Unaudited Consolidated Statements of Cash Flows for the three months ended June 30, 2025 and 2024. F-4

Notes to Financial Statements (Unaudited)

Notes to Financial Statements (Unaudited). F-5 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations. 4 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk. 6 Item 4.

Controls and Procedures

Controls and Procedures. 6

Other Information

Part II. Other Information Item 1. Legal Proceedings. 7 Item 1A.

Risk Factors

Risk Factors 7 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. 7 Item 3. Defaults Upon Senior Securities. 7 Item 4. Mine Safety Disclosures. 7 Item 5. Other Information. 7 Item 6. Exhibits. 8

Signatures

Signatures 9 Table of Contents CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q of Agentix Corp., a Nevada corporation (the "Company"), contains "forward-looking statements," as defined in the United States Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "could", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential" or "continue" or the negative of such terms and other comparable terminology. These forward-looking statements include, without limitation, statements about our market opportunity, our strategies, competition, expected activities and expenditures as we pursue our business plan, and the adequacy of our available cash resources. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Actual results may differ materially from the predictions discussed in these forward-looking statements. The economic environment within which we operate could materially affect our actual results. Additional factors that could materially affect these forward-looking statements and/or predictions include, among other things: the Company's need for and ability to obtain additional financing, product demand, market and customer acceptance, competition, public health crises, pricing and development difficulties, as well as general industry and market conditions and growth rates, general economic conditions, and other factors over which we have little or no control; and other factors discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). Our management has included projections and estimates in this Form 10-Q, which are based primarily on management's experience in the industry, assessments of our results of operations, discuss

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS. Agentix Corp. and Subsidiaries Consolidated Balance Sheets June 30, 2025 March 31, 2025 (Unaudited) Assets Current Assets Cash $ 4,412 $ 4,477 Prepaid expense and other current assets - 95,797 Total current assets 4,412 100,274 Total assets $ 4,412 $ 100,274 Liabilities and Stockholders' Deficit Current Liabilities Accounts payable $ 700,149 $ 968,888 Accounts payable - related parties 2,148,663 1,932,438 Note payable - related party 343,000 243,000 Accrued expenses 84,366 60,197 Total current liabilities 3,276,178 3,204,523 Long Term Liabilities - - Total liabilities 3,276,178 3,204,523 Commitments and Contingencies - - Stockholders' Deficit Common stock par value $ 0.001 : 50,000,000 shares authorized; 40,066,951 shares issued and outstanding as of June 30, 2025 and March 31, 2025, respectively 40,067 40,067 Common stock to be issued ( 357,102 at June 30, 2025 and March 31, 2025, respectively) 53,535 53,535 Additional paid-in capital 3,288,296 3,288,296 Accumulated other comprehensive income 53,688 35,381 Accumulated deficit ( 6,707,352 ) ( 6,521,528 ) Total stockholders' deficit ( 3,271,766 ) ( 3,104,249 ) Total liabilities and stockholders' deficit $ 4,412 $ 100,274 See accompanying notes to the unaudited consolidated financial statements. F-1 Table of Contents Agentix Corp. and Subsidiaries Unaudited Consolidated Statements of Operations Three Months Three Months Ended Ended June 30, 2025 June 30, 2024 Operating Expenses Professional fees $ 82,625 $ 77,000 Research and development 100,000 55,501 General and administrative expenses 17,717 18,804 Total operating expenses 200,342 151,305 Loss from operations ( 200,342 ) ( 151,305 ) Other (income) expense Foreign exchange gain ( 15,140 ) ( 8,223 ) Interest expense, net 21,226 7,635 Other income ( 20,604

View Full Filing

View this 10-Q filing on SEC EDGAR